ImmunoGen Stock News

Subscribers to  Chart of the Week  received this commentary on Sunday, August 27.

Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502,

The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon

Subscribers to Schaeffer's Event Trader  service scored a 272% profit with our  ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation.

ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.24 per share a year ago.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will ho

ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke through the 20-day moving average, which suggests a shor

ImmunoGen's Q1 2023 revenue increased to $49.9 million, primarily due to sales of Elahere and an upfront fee from Vertex Pharmaceuticals. The company plans to close a $325 million public offering. The

Navigating the choppy waters in the biotech sphere can be daunting, which makes it a challenge to hunt for the top high return biotech stocks. The journey to market approval, encumbered by volatile cl

The scorching 2023 S&P 500 market rally has been red hot.  As a result, we're seeing quite a few sizzling market outperformers.

ImmunoGen Inc. NASDAQ: IMGN is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver cancer-killin

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference.

ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.

The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our